Introduction {#s1}
============

Angiotensinogen (AGT) is a liver protein that interacts with renin to produce angiotensin I, the pro-hormone of angiotensin II. Angiotensin II is the major effector molecule of the renin-angiotensin-aldosterone system (RAAS) and plays a key role in the regulation of blood pressure (BP) by increasing vascular tone and promoting sodium retention. Genetic variants in the angiotensinogen gene modify the plasma concentration of angiotensinogen, which has been directly related to arterial blood pressure [@pone.0002533-Jeunemaitre1]. The molecular variant (M235T) of the *AGT* gene, encoding a threonine instead of a methionine at residue 235 of the mature protein, has been associated with a higher plasma AGT level and higher BP in patients homozygous for the T allele and occurs among various ethnic populations [@pone.0002533-Jeunemaitre1]--[@pone.0002533-Paillard1]. In a meta-analysis, the TT genotype was associated with a 32% increase in the risk of hypertension in white people but not in non-white people, when compared with the MM genotype [@pone.0002533-Staessen1].

Given the importance of hypertension in the occurrence of coronary heart disease [@pone.0002533-Sattar1], this finding suggests that this polymorphism may be related to increased risk of CHD. A few studies [@pone.0002533-Ludwig1]--[@pone.0002533-RodriguezPerez1], including recent publications, [@pone.0002533-Lanz1], [@pone.0002533-Sekuri1] have found that there is an association of the M235T *AGT* variant with increased CHD risk; however, this relationship was not confirmed in several other studies [@pone.0002533-Nair1]--[@pone.0002533-Tiret1] as well as in a meta-analysis [@pone.0002533-Sethi2]. Marked ethnic differences in the frequency of the T allele, small sample sizes and genotyping or phenotyping errors could partly account for discrepancies among these gene-disease association studies. Therefore, we investigated the association of the M235T polymorphism in the *AGT* gene (National Center for Biotechnology Information single nucleotide polymorphism cluster ID rs699) with acute myocardial infarction (AMI) and CHD in a large population-based cohort of middle-aged Dutch women and conducted an updated meta-analysis of the available studies to clarify the role of the M235T polymorphism in CHD risk.

Methods {#s2}
=======

Case-cohort study {#s2a}
-----------------

Study design, general questionnaire, anthropometric and laboratory measurements have been described in detail elsewhere [@pone.0002533-Boker1]--[@pone.0002533-Zafarmand1]. Briefly, the study population consisted of participants of the Prospect-EPIC cohort. Participants were recruited between 1993 and 1997 among women living in Utrecht and the vicinity who attended the regional population-based breast cancer-screening program. A total of 17,357 women, aged 49--70, were included. At baseline, a general and a dietary questionnaire were administered, a limited physical examination was performed and a non-fasting blood sample was taken. Follow-up event information was obtained from the Dutch Centre for Health Care Information, which holds a standardized computerized register of hospital discharge diagnoses. Using the International Classification of Diseases, ninth Revision (ICD-9) codes for the main discharge reason, we categorized cardiovascular disease (codes 390--459) as CHD (codes 410--414), including AMI (code 410), and other cardiovascular diseases. Whenever multiple events (AMI and CHD) occurred, the first occurrence of that endpoint was taken as the endpoint of interest in endpoint-specific analyses. All women signed an informed consent form prior to study inclusion. The study was approved by the Institutional Review Board of the University Medical Center Utrecht.

We applied the case-cohort design introduced by Prentice [@pone.0002533-Prentice1]. From the 17,357 women in the total cohort, we randomly selected a sample of 10% as the sub-cohort (n = l736). Women who did not consent to linkage with vital status registries or who were not traceable (cases n = 3/sub-cohort n = 38) were not included. Women who reported a diagnosis of cardiovascular disease (ICD-9; 390--459) at baseline or who had missing questionnaires, blood, or DNA samples were excluded. This resulted in 15,236 women in the total cohort and 1522 women in the sub-cohort (as the control group) at baseline. All individuals with first fatal and non-fatal CHD and ischemic stroke events that arose during follow-up until January 1^st^ 2000 were selected as cases. These were 211 CHD cases, including 71 AMIs. For all case subjects, follow-up ended at the date of diagnosis or at the date of death due to cardiovascular disease.

### Genetic analysis {#s2a1}

Genetic analysis was performed at the Cardiovascular Genotyping (CAGT) laboratory of the Department of Internal Medicine of the University Hospital Maastricht. Genomic DNA was extracted from buffy coats using the QIAamp® Blood Kit (Qiagen Inc., Valencia, California, USA). Genotyping of the polymorphisms was performed using a multilocus genotyping assay for candidate markers of cardiovascular disease risk (Roche Molecular Systems Inc., Pleasanton, CA, USA) [@pone.0002533-Cheng1]. Briefly, each DNA sample was amplified using two multiplex polymerase chain reactions, and the alleles were genotyped simultaneously using an array of immobilized sequence-specific oligonucleotide probes. This array of probes was blotted on plastic strips, and, after staining, genotypes were scored based on blue (positive) and white (negative) bands. Each blue band, representing a specific genotype, was scored by specific software (counting the pixel intensity of each band) and checked manually. Genotyping was performed blinded to the case-control status. A random double-check was performed to detect potential genotyping errors in a subset of 100 samples. The check confirmed the previous genotyping results by 100%.

### Data analysis {#s2a2}

Hardy-Weinberg equilibrium (HWE) was tested with the χ^2^ test among the controls. Allele frequencies were estimated by gene counting. We used the ANOVA *F* test to estimate relationships among the M235T genotypes and continuous variables, while we tested the significance of any difference in proportions by applying the χ^2^ statistic. A p-value \<0.05 (2-sided) was considered statistically significant.

To assess the relationship of the M235T polymorphism in the *AGT* gene with the outcome, we used a Cox proportional hazards model with an estimation procedure adapted for case-cohort designs. We used the unweighted method by Prentice [@pone.0002533-Prentice1], [@pone.0002533-OnlandMoret1], which is incorporated in a SAS macro at <http://lib.stat.cmu.edu/general/robphreg>. A previous meta-analysis [@pone.0002533-Sethi2] showed that the effect of the *AGT* M235T variant on its intermediate phenotype (plasma angiotensinogen level) follows an additive model according to the number of T alleles \[5% (95% CI: 2 to 8%) increase for the MT and 11% (95% CI: 7 to 15%) increase for the TT genotype versus the MM genotype\]. Therefore, our *priori* hypothesis was that the association between the M235T polymorphism in the *AGT* gene and CHD follows an additive model according to the number of T alleles. However, other genetic models were evaluated as well. We considered different modes of inheritance as follows: *the additive "per-allele" model*, the T allele was compared between cases and controls by assigning scores of 0, 1, and 2 to homozygotes for the M allele, heterozygotes, and homozygotes for the T allele, respectively; *the recessive model*, the TT genotype versus the MT and MM combined genotypes; and *the dominant model*, the MT and TT genotypes combined versus the MM genotype. We also performed separate pairwise comparisons of the MT and TT genotypes versus the MM genotype.

Meta-analysis {#s2b}
-------------

### Searching {#s2b1}

We searched PubMed/MEDLINE, Web of Science, and EMBASE up to February 2007 for observational studies evaluating an association between the M235T polymorphism in the *AGT* gene and CHD. Terms used for the search contained both medical subject heading terms and text words: (Met235Thr OR M235T OR T704C) AND (angiotensinogen OR *AGT*) AND (polymorphism OR mutation OR genetic OR genotype) AND ("coronary disease" OR "coronary heart disease" OR CHD OR "myocardial infarction" OR MI OR "myocardial infarct" OR "coronary artery disease" OR CAD OR "ischemic heart disease" OR IHD OR "cardiovascular disease" OR "heart disease" OR angina). We also retrieved additional studies by hand searching the bibliographies of original research reports and review articles and through the MEDLINE option "related articles". Search results were limited to articles published in English and studies on human subjects.

### Selection {#s2b2}

All studies were considered potentially eligible if they aimed to investigate the relationship between the M235T genotypes and risk of CHD or MI. Any observational study, regardless of sample size, which fulfilled the following criteria, was included: (i) *AGT* M235T genotype frequencies were provided by case-control status (studies without controls were excluded); (ii) risk of CHD or MI was evaluated (studies on recurrent coronary events were excluded); (iii) relevant data were presented to calculate the effect size and its 95% CI; (iv) non-overlapping data were contained. For duplicate publications, the study with the smaller data set was excluded.

### Data abstraction {#s2b3}

The following information was extracted from each study that we included: the first author\'s name; country; year of publication; the population evaluated; study design; mean age or age range for case-patients and controls; definition and number of cases and controls; allele frequencies and genotype distribution in case-patients and controls (where data were not given, they were calculated from the corresponding genotyping frequencies of the case and control groups); consistency of genotype frequencies with HWE (calculated); gender in the evaluated population and male percentage, matching variables, use of blinding of genotyping staff, performing regenotyping of a random sample, and crude ORs and 95% CIs for development of CHD or MI related to the *AGT* gene genotypes based on different genetic models (from the original paper or calculated from crude data if not provided). We again considered a dominant, a recessive, an additive "per-allele" model and pairwise comparisons. Data were extracted independently and entered into separate databases by two authors (performed by MHZ and MLB). Results were compared, and disagreements were resolved by a consensus.

### Quantitative data synthesis {#s2b4}

The method of Mantel-Haenszel was used to calculate the odds ratio for the pooled data in a fixed-effects model, and, if there was evidence for heterogeneity, the DerSimonian-Laird method was used for the pooled odds ratio in a random-effects model, under pairwise comparisons of the different genotypes and dominant, recessive, and additive inheritance models. For all the models used, the T allele was considered the risk allele. The genetic model to be considered as the *priori* hypothesis was the additive model. In each study, we tested for HWE by using the χ^2^ test or an exact test among the controls by using the genhwi command in Stata 9.2 [@pone.0002533-Trikalinos1].

In addition, we used Cochran\'s χ^2^ -- based ***Q*** statistic for between-study heterogeneity, which is considered to be significant for *P*\<0.10, as well as the ***I^2^*** statistic for estimation of inconsistency in meta-analyses [@pone.0002533-Trikalinos1]. ***I^2^*** represents the percentage of the observed between-study variability due to heterogeneity rather than to chance. It ranges between 0% and 100%, where a value of 0% indicates no observed heterogeneity, and larger values indicate an increasing degree of heterogeneity (roughly suggested cut-off points include: ***I^2^*** = 0--25%, no heterogeneity; ***I^2^*** = 25--50%, moderate heterogeneity; ***I^2^*** = 50--75%, large heterogeneity; ***I^2^*** = 75--100%, extreme heterogeneity) [@pone.0002533-Higgins1].

We used funnel plots to examine the publication bias of reported associations. We also used Egger\'s test and the Begg-Mazumdar test with 95% CI for evaluation of publication bias, which are considered to be significant for *P*\<0.10. Meta-analysis was carried out using STATA 9.2. We used random effect meta-regression models with restricted maximum likelihood estimation to evaluate the extent to which different variables explained heterogeneity among the individual ORs. The pre-specified characteristics for assessment of sources of inter-study heterogeneity were: study size (for detailed definition see [@pone.0002533-AgerholmLarsen1]); ethnicity of population evaluated (of Caucasian descent, East Asian, and others); male percentage in each study, matching (matched or unmatched); blinding of genotyping staff (blinded, or not reported); performing regenotyping of a random sample (performed or not reported); violating HWE (violated or confirmed; the term "violated" used for statistically significant deviation of HWE) in sub-group analysis as well as in meta-regression analysis.

### HWE Correction {#s2b5}

For evaluating the impact of HWE-violated studies on effect estimates (at the 0.05 significance level) under different genetic models, odds ratios, and variances were corrected by using the HWE-predicted genotype counts in the control instead of the observed counts as previously suggested [@pone.0002533-Trikalinos1]. Thereafter, they were included in the sensitivity analysis.

Results {#s3}
=======

Prospect-EPIC study results {#s3a}
---------------------------

The general characteristics of the randomly sampled participants of the cohort (N = 1522) are given in [Table 1](#pone-0002533-t001){ref-type="table"}. The genotype distribution was in Hardy-Weinberg equilibrium (χ^2^ = *0.020*; *P* = *0.89*). General and clinical characteristics of CHD cases and controls are shown in [Table 1](#pone-0002533-t001){ref-type="table"}. The median follow up time for the random sample was 4.3 years, with a total of 6,523 person years. The actual follow-up in the baseline cohort of 15,236 women was 64,768 person years. Due to the case-cohort design, 23 women in the sub-cohort eventually were CHD cases (among which there were nine AMI cases).

10.1371/journal.pone.0002533.t001

###### Baseline characteristics of the sub-cohort according to genotype, and clinical characteristics of CHD cases and controls in the Prospect --Epic cohort.
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  Characteristics                                                      sub-cohort (N = 1522)   *P*-value[b](#nt103){ref-type="table-fn"}    CHD cases    Sub-cohort   *P*-value[c](#nt104){ref-type="table-fn"}                         
  ------------------------------------------------------------------- ----------------------- ------------------------------------------- ------------- ------------ ------------------------------------------- ------------- -------- --------
  N total (%)                                                               535 (35.2)                        737 (48.4)                   250 (16.4)        \-                          210                         1522         \-    
  Age at intake (yr) [a](#nt102){ref-type="table-fn"}                        57.1±5.8                          57.1±6.2                     57.4±6.3        0.83                      60.5±5.9                     57.1±6.1     \<0.01  
  Body mass index (kg/m^2^) [a](#nt102){ref-type="table-fn"}                 26.0±4.1                          25.6±3.8                     25.8±4.1        0.19                      26.8±3.9                     25.8±4.0     \<0.01  
  Weight (kg) [a](#nt102){ref-type="table-fn"}                                 70±11                             69±11                        69±11         0.17                        71±11                        69±11       0.07   
  Height (cm) [a](#nt102){ref-type="table-fn"}                               164.4±5.9                         164.2±6.0                    164.0±6.1       0.66                      162.8±6.0                    164.3±6.0    \<0.01  
  Waist to hip ratio [a](#nt102){ref-type="table-fn"}                       0.794±0.057                       0.786±0.058                  0.786±0.055      0.03                     0.813±0.060                  0.789±0.057   \<0.01  
  Hypertension (%) [d](#nt105){ref-type="table-fn"}                            39.4                              41.2                         48.4          0.06                        60.5                         41.8       \<0.01  
  Systolic blood pressure (mm Hg) [a](#nt102){ref-type="table-fn"}            131±19                            133±21                       135±20         0.07                       143±22                       133±20      \<0.01  
  Diastolic blood pressure (mm Hg) [a](#nt102){ref-type="table-fn"}            79±10                             79±11                        80±11         0.14                        82±11                        79±11      \<0.01  
  Presence of diabetes (%)                                                      2.2                               2.0                          2.8          0.78                         5.7                          2.2       \<0.01  
  Presence of hypercholesterolemia (%)                                          3.6                               4.6                          2.8          0.38                        11.4                          3.9       \<0.01  
  Current alcohol consumption (%)                                              88.7                              87.1                         89.2          0.60                        80.7                         88.0       \<0.01  
  Smoking status (%)                                                           Past                              35.1                         33.8          36.4                        0.73                         26.2        34.7     0.02
                                                                              Current                            23.2                         22.4          23.6                        0.90                         33.8        22.9    \<0.01
  Pack- years [e](#nt106){ref-type="table-fn"}                                6.8±9.5                           6.5±9.5                      6.7±9.3        0.87                      9.7±11.4                      6.7±9.5     \<0.01  
  Total cholesterol (mmol/L) [a](#nt102){ref-type="table-fn"}                 5.9±1.0                           5.8±0.9                      5.9±1.1        0.05                       6.4±1.0                      5.9±1.0     \<0.01  
  HDL cholesterol (mmol/L) [a](#nt102){ref-type="table-fn"}                   1.6±0.4                           1.6±0.4                      1.6±0.4        0.33                       1.4±0.3                      1.6±0.4     \<0.01  
  LDL cholesterol (mmol/L) [a](#nt102){ref-type="table-fn"}                   4.0±1.0                           3.9±0.9                      3.9±0.9        0.25                       4.4±1.0                      3.9±0.9     \<0.01  
  Serum glucose (mmol/L) [a](#nt102){ref-type="table-fn"}                     4.6±1.5                           4.5±1.3                      4.5±1.2        0.52                       5.1±2.5                      4.5±1.4     \<0.01  

HDL, high-density lipoprotein; LDL, low-density lipoprotein; CHD, coronary heart disease (ICD 410--414).

Mean±standard deviation.

Comparison of risk factors across genotypes, using the ANOVA *F* test (continuous variables) and the χ^2^ statistic (categorical variables).

Comparison of risk factors across disease status, using the *independent samples t-test* (continuous variables) and the χ^2^ statistic (categorical variables).

Defined as a systolic blood pressure ≥140 mm Hg and/or diastolic blood pressure ≥90 mm Hg and/or questionnaire positive.

The number of packs of cigarettes smoked per day by the number of years the person has smoked.

Due to the association of the M235T genotypes with some risk factors of CHD, we presented crude models and models adjusted for hypertension, total cholesterol and waist to hip ratio as potential confounding factors. [Table 2](#pone-0002533-t002){ref-type="table"} presents hazard ratios of AMI and CHD under different genetic models. Under the additive model of inheritance, no increased risk for CHD was found (HR = 1.20; 95% CI, 0.86 to 1.68; *P* = *0.28*), which did not alter after adjustment (HR = 1.17; 95% CI, 0.83 to 1.64; *P* = *0.38*). The same was true for other comparisons ([Table 2](#pone-0002533-t002){ref-type="table"}). Analyses for AMI risk did not show any statistically significant associations ([Table 2](#pone-0002533-t002){ref-type="table"}).

10.1371/journal.pone.0002533.t002

###### Association of the *AGT* M235T polymorphism and AMI and CHD under different genetic models.
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  Mode of Inheritance                          Crude: model 1   Adjusted: model 2 [b](#nt109){ref-type="table-fn"}                               
  ------------------------------------------- ---------------- ---------------------------------------------------- ------ ------ -------------- ------
  **AMI**                                                                                                                                        
  Additive [a](#nt108){ref-type="table-fn"}         1.20                            0.86--1.68                       0.28   1.17    0.83--1.64    0.38
  Recessive (TT vs. M-carriers)                     0.77                            0.43--1.41                       0.40   0.87    0.46--1.58    0.62
  Dominant (T-carriers vs. MM)                      0.79                            0.47--1.32                       0.36   0.79    0.46--1.33    0.37
  MT vs. MM                                         1.09                            0.84--1.41                       0.53   1.11   0\. 85--1.45   0.45
  TT vs. MM                                         1.21                            0.86--1.70                       0.28   1.17    0.83--1.63    0.38
  **CHD**                                                                                                                                        
  Additive [a](#nt108){ref-type="table-fn"}         1.14                            0.93--1.39                       0.20   1.11    0.90--1.38    0.33
  Recessive (TT vs. M-carriers)                     0.87                            0.60--1.26                       0.45   0.98    0.66--1.47    0.93
  Dominant (T-carriers vs. MM)                      0.82                            0.60--1.12                       0.21   0.80    0.58--1.10    0.18
  MT vs. MM                                         1.09                            0.93--1.27                       0.31   1.13    0.95--1.34    0.16
  TT vs. MM                                         1.14                            0.93--1.40                       0.20   1.11    0.90--1.37    0.33

AMI = acute myocardial infarction (ICD 410); CHD = coronary heart disease (ICD 410--414).

The additive genetic model assumes that there is a linear gradient in risk between the MM, MT and TT genotypes (MM genotype baseline). This is equivalent to a comparison of the T allele versus the M allele (baseline).

We used a cox proportional hazards model with an estimation procedure adapted for case-cohort designs; adjusted for waist to hip ratio, hypertension, total cholesterol.

Meta-Analysis results {#s3b}
---------------------

***Flow of included studies***. A total of 44 gene-disease association studies, including the present study, evaluating the *AGT* M235T gene variant and CHD risk were identified. Seven articles were excluded, three of which were duplicate publications [@pone.0002533-Sethi1], [@pone.0002533-Berdeli1], [@pone.0002533-FernandezArcas1], three of which did not provide relevant data [@pone.0002533-Zee1]--[@pone.0002533-Krizanova1], and one of which studied the risk of recurrent coronary events [@pone.0002533-Goldenberg1]. Finally, 37 studies met the selection criteria. In one paper, the provided results were based on two different studies [@pone.0002533-Ludwig1], so both were included in the meta-analysis. Therefore, 38 studies with 13,284 cases and 18,722 controls were included in the final meta-analysis ([Figure 1](#pone-0002533-g001){ref-type="fig"}).

![Flow chart of study selection.](pone.0002533.g001){#pone-0002533-g001}

Study characteristics {#s3c}
---------------------

Characteristics of the studies are shown in [Table 3](#pone-0002533-t003){ref-type="table"} [@pone.0002533-Ludwig1]--[@pone.0002533-RodriguezPerez1], [@pone.0002533-Sekuri1], [@pone.0002533-Nair1], [@pone.0002533-Tiret1], [@pone.0002533-Sethi3]--[@pone.0002533-YamakawaKobayashi1]. There were 25 studies in Caucasians, eight studies in East Asians, and five studies in other populations (West Asian, South Asian, African, African-American, and South American). The last was collapsed into a miscellaneous group. The design of the studies was case-control, except for three studies that were prospective cohort [@pone.0002533-Wierzbicki1], case-cohort (present study), and cross-sectional [@pone.0002533-Gardemann1]. The T allele frequency varied from 26 to 54 percent in Caucasians, 65 to 91 percent in East Asians, and 34 to 83 percent in the miscellaneous group.

10.1371/journal.pone.0002533.t003

###### Characteristics of published studies of the association between the M235T polymorphism in *AGT* gene and CHD included in the meta-analysis.
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                                   Author                              Year      Country          Ethnicity       Total cases   Total controls   Study size based on average weight   Cases MM   Cases MT   Cases TT   Controls MM   Controls MT   Controls TT
  ---- -------------------------------------------------------------- ------ --------------- ------------------- ------------- ---------------- ------------------------------------ ---------- ---------- ---------- ------------- ------------- -------------
  1               Katsuya et al. [@pone.0002533-Katsuya1]              1995    New Zealand        Caucasian           422            406                       Large                    144        186         92          156           191           59
  2                 Tiret et al. [@pone.0002533-Tiret1]                1995   France and UK       Caucasian           630            741                       Large                    229        301        100          258           372           111
  3     Ludwig et al.^a^ [@pone.0002533-Ludwig1] (Framingham study)    1997        USA            Caucasian           58              55                       Small                     17         30         11          20            23            12
  4        Ludwig et al.^b^ [@pone.0002533-Ludwig1] (ARIC study)       1997        USA            Caucasian           255            245                       Large                     79        117         59          85            118           42
  5                Wenzel et al. [@pone.0002533-Wenzel1]               1997      Germany          Caucasian           111            102                       Small                     25         59         27          39            46            17
  6            Winkelmann et al. [@pone.0002533-Winkelmann1]           1999      Germany          Caucasian           329             92                       Small                    103        148         78          28            53            11
  7        Fernandez-Arcas et al. [@pone.0002533-FernandezArcas2]      1999       Spain           Caucasian           272            182                       Small                     84        132         56          36            96            50
  8             Gardemann et al. [@pone.0002533-Gardemann1]            1999      Germany          Caucasian          1739            511                       Large                    536        920        283          168           247           96
  9                Fatini et al. [@pone.0002533-Fatini1]               2000       Italy           Caucasian           205            209                       Small                     61         91         53          84            86            39
  10            Fomicheva et al. [@pone.0002533-Fomicheva1]            2000      Russia           Caucasian           198            152                       Small                     63         85         50          43            75            34
  11            Reinhardt et al. [@pone.0002533-Reinhardt1]            2000      Germany          Caucasian           184            155                       Small                     56        101         27          38            91            26
  12              Batalla et al. [@pone.0002533-Batalla1]              2000       Spain           Caucasian           220            200                       Small                     69         99         52          64            96            40
  13           Wierzbicki et al. [@pone.0002533-Wierzbicki1]           2000        UK             Caucasian           48             108                       Small                     23         21         4           58            44             6
  14       Rodriguez-Perez et al. [@pone.0002533-RodriguezPerez1]      2001       Spain           Caucasian           299            315                       Large                     67        145         87          97            158           60
  15             Olivieri et al. [@pone.0002533-Olivieri1]             2001       Italy           Caucasian           454            245                       Large                    148        205        101          74            114           57
  16                Sethi et al. [@pone.0002533-Sethi3]                2001      Denmark          Caucasian           943            7975                      Large                    335        460        148         2779          3886          1310
  17              Ortlepp et al. [@pone.0002533-Ortlepp1]              2002      Germany          Caucasian           100            100                       Small                     25         58         17          29            55            16
  18                Ermis et al. [@pone.0002533-Ermis1]                2002      Turkey           Caucasian           102            114                       Small                     32         48         22          39            59            16
  19                  Bis et al. [@pone.0002533-Bis1]                  2003        USA            Caucasian           208            717                       Large                     71         98         39          215           349           153
  20          Buraczynska et al. [@pone.0002533-Buraczynska1]          2003      Poland           Caucasian           200            200                       Small                     28        122         50          72            80            48
  21                Tobin et al. [@pone.0002533-Tobin1]                2004        UK             Caucasian           547            505                       Large                    212        252         83          197           226           82
  22               Sekuri et al. [@pone.0002533-Sekuri1]               2005      Turkey           Caucasian           115            128                       Small                     46         42         27          33            71            24
  23               Methot et al. [@pone.0002533-Methot1]               2005      Canada           Caucasian           198            149                       Small                     65         93         40          60            70            19
  24               Renner et al. [@pone.0002533-Renner1]               2005      Austria          Caucasian          2582            732                       Large                    841        1205       536          237           357           138
  25                  Zafarmand et al. (present study)                 2008    Netherlands        Caucasian           210            1522                      Large                     64        108         38          535           737           250
  26             Kamitani et al. [@pone.0002533-Kamitani1]             1995       Japan          East Asian           103            103                       Small                     6          31         66          10            41            52
  27             Ishigami et al. [@pone.0002533-Ishigami1]             1995       Japan          East Asian           82             160                       Small                     6          22         54          30            51            79
  28    Yamakawa-Kobayashi et al. [@pone.0002533-YamakawaKobayashi1]   1995       Japan          East Asian           315            380                       Small                     15         91        209           9            131           240
  29                   Ko et al. [@pone.0002533-Ko1]                   1997       China          East Asian           267            337                       Small                     6          36        225           4            54            279
  30             Ichihara et al. [@pone.0002533-Ichihara1]             1997       Japan          East Asian           327            352                       Small                     15        103        209          13            112           227
  31                 Cong et al. [@pone.0002533-Cong1]                 1998       Japan          East Asian           104            170                       Small                     2          31         71          16            43            111
  32                 Sheu et al. [@pone.0002533-Sheu1]                 1998       China          East Asian           102            145                       Small                     1          26         75           1            37            107
  33                 Tsai et al. [@pone.0002533-Tsai1]                 2006      Taiwan          East Asian           735            519                       Large                     15        195        525           5            111           403
  34             Frossard et al. [@pone.0002533-Frossard1]             1998        UAE              Arab              74              61                       Small                     21         32         21          16            26            19
  35               Hooper et al. [@pone.0002533-Hooper1]               2002        USA        African- American       100            100                       Small                     4          29         67           2            31            67
  36                 Nair et al. [@pone.0002533-Nair1]                 2003       India          South Asian          141            131                       Small                     9          36         96          11            40            80
  37               Araujo et al. [@pone.0002533-Araujo1]               2004      Brazil        South American         110            104                       Small                     46         52         12          43            51            10
  38              Ranjith et al. [@pone.0002533-Ranjith1]              2004   South Africa         African            195            300                       Small                     24         80         91          29            127           144

  Author                                                           Study design        Mean age±SD (years) in Cases         Mean age±SD (years) in Controls     Sex   Male percent                                             Matching variable (s)                                              Allele frequency 235T (%)                 *P (HWE)*                 Blinding of genotyping staff   Regenotyping of random subsample
  -------------------------------------------------------------- ----------------- ------------------------------------- ------------------------------------- ----- -------------- ------------------------------------------------------------------------------------------------------------ --------------------------- --------------------------------------- ------------------------------ ----------------------------------
  Katsuya et al. [@pone.0002533-Katsuya1]                          Case-control                    62±7                                  62±7                   M/F        NR                                                           None                                                                 38                               0.97                                 NR                               NR
  Tiret et al. [@pone.0002533-Tiret1]                              Case-control                   54±0.3                                53±0.3                   M        100                                                           Age                                                                  40                               0.22                                 NR                               NR
  Ludwig et al.^a^ [@pone.0002533-Ludwig1] (Framingham study)      Case-control                     NR                                    NR                    M/F        86                                                       Age and sex                                                              43                               0.28                                 NR                               NR
  Ludwig et al.^b^ [@pone.0002533-Ludwig1] (ARIC study)            Case-control                     NR                                    NR                    M/F       80.5                                                      Age and sex                                                              41                               0.92                                 NR                               NR
  Wenzel et al. [@pone.0002533-Wenzel1]                            Case-control     42[\*](#nt111){ref-type="table-fn"}   38[\*](#nt111){ref-type="table-fn"}   M/F        88                                                           None                                                                 39                               0.59                                 NR                               NR
  Winkelmann et al. [@pone.0002533-Winkelmann1]                    Case-control                    56±10                                 56±10                   M        100                                                           None                                                                 41                               0.06                                 NR                               NR
  Fernandez-Arcas et al. [@pone.0002533-FernandezArcas2]           Case-control                    67±7                                  60±10                  M/F        42                                                           None                                                                 54                               0.41                                 NR                              Yes
  Gardemann et al. [@pone.0002533-Gardemann1]                     Cross-sectional                  63±9                                  59±11                   M        100                                                           None                                                                 43                               0.76                                 NR                               NR
  Fatini et al. [@pone.0002533-Fatini1]                            Case-control                    59±5                                  51±6                   M/F        76                                                           None                                                                 39                              0.0476                                NR                               NR
  Fomicheva et al. [@pone.0002533-Fomicheva1]                      Case-control                     67                                    11                     M        100                                                           None                                                                 47                               0.90                                 NR                               NR
  Reinhardt et al. [@pone.0002533-Reinhardt1]                      Case-control                    57±11                                 56±14                  M/F        62                                                           None                                                                 46                              0.0240                               Yes                              Yes
  Batalla et al. [@pone.0002533-Batalla1]                          Case-control                    43±5                                  42±6                    M        100                                                    Age and ethnicity                                                           44                               0.71                                 NR                               NR
  Wierzbicki et al. [@pone.0002533-Wierzbicki1]                       Cohort                       57±13                                 53±12                  M/F        68                                                           None                                                                 26                               0.53                                Yes                              Yes
  Rodriguez-Perez et al. [@pone.0002533-RodriguezPerez1]           Case-control                    56±10                                 54±10                  M/F        76                                                           None                                                                 44                               0.76                                Yes                               NR
  Olivieri et al. [@pone.0002533-Olivieri1]                        Case-control                    60±9                                  58±13                  M/F       83.5                                                          None                                                                 47                               0.31                                 NR                               NR
  Sethi et al. [@pone.0002533-Sethi3]                              Case-control                    59±9                                  56±15                  M/F        74                                                           None                                                                 41                               0.43                                 NR                               NR
  Ortlepp et al. [@pone.0002533-Ortlepp1]                          Case-control                    58±13                                 59±11                  M/F        68                                Age, sex, and prevalence of standard cardiac risk factors                                       43                               0.23                                 NR                               NR
  Ermis et al. [@pone.0002533-Ermis1]                              Case-control                    42±12                                 40±13                  NR         NR                                                           None                                                                 40                               0.40                                 NR                               NR
  Bis et al. [@pone.0002533-Bis1]                                  Case-control                     70                                    64                    M/F       61.5                                      Age, sex and calendar year of identification                                             46                               0.61                                Yes                               NR
  Buraczynska et al. [@pone.0002533-Buraczynska1]                  Case-control                    53±7                                  47±11                   M        100                                                           None                                                                 44                              0.0077                                NR                               NR
  Tobin et al. [@pone.0002533-Tobin1]                              Case-control                    62±9                                  57±11                  M/F        68                                                           None                                                                 39                               0.21                                 NR                              Yes
  Sekuri et al. [@pone.0002533-Sekuri1]                            Case-control                    48±8                                  44±7                   M/F       77.4                                                          None                                                                 47                               0.19                                 NR                               NR
  Methot et al. [@pone.0002533-Methot1]                            Case-control                    63±10                                 62±7                    F         0                                                            Age                                                                  37                               0.84                                 NR                               NR
  Renner et al. [@pone.0002533-Renner1]                            Case-control                    64±10                                 58±12                  M/F       74.8                                                          None                                                                 43                               0.86                                Yes                               NR
  Zafarmand et al. (present study)                                  Case-cohort                    61±6                                  57±6                    F         0                                                            None                                                                 41                               0.89                                Yes                              Yes
  Kamitani et al. [@pone.0002533-Kamitani1]                        Case-control                    52±1                                  54±1                    M        100                    Age, sex, BMI, blood pressure, total cholesterol, smoking and history of diabetes                           70                               0.65                                 NR                               NR
  Ishigami et al. [@pone.0002533-Ishigami1]                        Case-control                    62±1                                  60±1                   M/F       68.3                                                          None                                                                 65                              0.0002                                NR                               NR
  Yamakawa-Kobayashi et al. [@pone.0002533-YamakawaKobayashi1]     Case-control                    57±8                                  51±8                   M/F        80                                                           None                                                                 80                               0.07                                 NR                               NR
  Ko et al. [@pone.0002533-Ko1]                                    Case-control                    62±1                                  56±1                   M/F        77                                                           None                                                                 91               0.51[\*](#nt111){ref-type="table-fn"}                NR                               NR
  Ichihara et al. [@pone.0002533-Ichihara1]                        Case-control                    53±6                                  53±5                    M        100        Age, sex, BMI and some CHD risk factors (history of smoking, hypertension, diabetes, hypercholesterolemia)              80                               0.86                                 NR                               NR
  Cong et al. [@pone.0002533-Cong1]                                Case-control                    65±1                                   NR                    M/F        76                                                           None                                                                 78                              0.0006                                NR                               NR
  Sheu et al. [@pone.0002533-Sheu1]                                Case-control                    63±1                                  58±1                    M        100                                                           None                                                                 87               0.47[\*](#nt111){ref-type="table-fn"}                NR                               NR
  Tsai et al. [@pone.0002533-Tsai1]                                Case-control                    64±11                                 59±13                  M/F       72.2                                                          None                                                                 88                               0.38                                 NR                               NR
  Frossard et al. [@pone.0002533-Frossard1]                        Case-control                    57±12                                 54±14                  M/F       48.2                                                          None                                                                 52                               0.26                                 NR                               NR
  Hooper et al. [@pone.0002533-Hooper1]                            Case-control                     NR                                    NR                    M/F        NR                                                           None                                                                 83               0.73[\*](#nt111){ref-type="table-fn"}                NR                               NR
  Nair et al. [@pone.0002533-Nair1]                                Case-control                    56±5                                  48±6                   M/F       82.3                                                      Age and sex                                                              76                               0.08                                 NR                               NR
  Araujo et al. [@pone.0002533-Araujo1]                            Case-control                     NR                                    NR                    M/F       66.6                                                          None                                                                 34                               0.36                                 NR                               NR
  Ranjith et al. [@pone.0002533-Ranjith1]                          Case-control                     NR                                    NR                    M/F        NR                                                           Age                                                                  69                               0.90                                 NR                               NR

  Author                                                          End point                                                                                                                                                           Case definition                                                                                                                                                                                                Source of controls
  -------------------------------------------------------------- ----------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------
  Katsuya et al. [@pone.0002533-Katsuya1]                            CHD                                                                                 Admission for treatment of myocardial infarction or unstable angina, PTCA, or CABG, or stable angina with angiographic evidence of CHD or a positive exercise test result                                                                               Controls without a history of CHD and symptoms suggesting angina from two previous studies
  Tiret et al. [@pone.0002533-Tiret1]                                MI                                                                                                                                                            WHO MONICA category I                                                                                                                                                                Electoral rolls in France and the list of general practitioners in N. Ireland
  Ludwig et al.^a^ [@pone.0002533-Ludwig1] (Framingham study)        CHD                                                                                                                                  Diagnosed MI by a physician, a PTCA, a CABG, prior MI in ECG, fatal CHD                                                                                                                               Healthy controls without the conditions, no lipid-lowering medications and no family history
  Ludwig et al.^b^ [@pone.0002533-Ludwig1] (ARIC study)              CHD                                                                                                              Diagnosed MI by a physician, a percutaneous coronary angioplasty, a coronary artery bypass, prior MI, fatal CHD                                                                                                           Healthy controls without the conditions, no lipid-lowering medications and no family history
  Wenzel et al. [@pone.0002533-Wenzel1]                              CHD                                                                                                                              \>50% stenosis of at least one major coronary vessel, defined as MI, PTCA, CABG                                                                                                                                                Healthy young persons without any symptoms for CVD
  Winkelmann et al. [@pone.0002533-Winkelmann1]                    CHD, MI                                                                                                                                                 At least one coronary stenosis ≥ 50%                                                                                                                                                               controls without coronary artery disease in coronary angiography
  Fernandez-Arcas et al. [@pone.0002533-FernandezArcas2]             MI                                                          Typical prolonged chest pain or atypical symptoms, acute congestive heart failure, syncope, and serial cardiac enzymes elevation exceeding twice the upper limit of reference range and dynamic ECG changes typical of MI                                                                     Healthy controls with no CVD using health service identity card
  Gardemann et al. [@pone.0002533-Gardemann1]                      CHD, MI                                                                                                                                        CHD: coronary stenosis ≥ 50% MI: Using the WHO criteria                                                                                                                                                               No vessel disease in the coronary angiography
  Fatini et al. [@pone.0002533-Fatini1]                              CHD                                                                                                                        History of CHD (previous MI or angina pectoris) with coronary stenosis \>75% by angiography                                                                                                                                       Random healthy controls from the staff of the University
  Fomicheva et al. [@pone.0002533-Fomicheva1]                        MI                                                                                                                                                           Using the WHO criteria                                                                                                                                                                                           From secondary schools
  Reinhardt et al. [@pone.0002533-Reinhardt1]                        CHD                                                                                                                         At least one coronary stenosis ≥ 50% of a major coronary artery with or without prior MI                                                                                                                                          Random healthy controls from the local registry office
  Batalla et al. [@pone.0002533-Batalla1]                            MI                                                                                                                                                             WHO MONICA protocol                                                                                                                                                                                 Healthy controls from residents of the region
  Wierzbicki et al. [@pone.0002533-Wierzbicki1]                      CHD                                                                                                                   Confirmed cardiac event, angioplasty, coronary bypass surgery, or significant lesions on angiography                                                                                                                                                            No CHD
  Rodriguez-Perez et al. [@pone.0002533-RodriguezPerez1]             CHD                                                                                                       Hospital-admitted with a diagnosis of MI or unstable angina and documented evidence of coronary artery disease by angiography                                                                                                                                     Random controls without CVD
  Olivieri et al. [@pone.0002533-Olivieri1]                        CHD, MI                                     CHD: Candidate patients for CABG, having \>50% stenosis of at least one major coronary vessel MI: By medical records showing diagnostic electrocardiogram and enzyme changes, and/or the typical sequelae of myocardial infarction on ventricular angiography                                    CHD-free group documented by angiography who were examined for other reasons in the institute
  Sethi et al. [@pone.0002533-Sethi3]                              CHD, MI                                                                                                                                  CHD: ICD, 8th edition, codes 410-414 MI: ICD, 8th edition, code 410                                                                                                                                          Random healthy controls without CHD, MI or CVA from the city of Copenhagen
  Ortlepp et al. [@pone.0002533-Ortlepp1]                            CHD                                                                                                                                              \>50% stenosis of at least one coronary vessel                                                                                                                                                            Patients without any signs of atherosclerosis in angiography
  Ermis et al. [@pone.0002533-Ermis1]                             Early MI                                                                                                                                                             WHO criteria                                                                                                                                                                          Healthy subjects without a history of CHD, hypertension or diabetes
  Bis et al. [@pone.0002533-Bis1]                                    MI                                                                                                                                         Criteria were adapted from the Cardiovascular Health Study                                                                                                                                            Randomly selected subjects from the members of a health maintenance organization
  Buraczynska et al. [@pone.0002533-Buraczynska1]                    CHD                                                                                                                                   Hospitalized patients with unstable angina, stable angina or acute MI                                                                                                                                                       Healthy subjects without family history of CHD
  Tobin et al. [@pone.0002533-Tobin1]                                MI                                                                                                                                                           Using the WHO criteria                                                                                                                                                                                        Healthy visitors to patients
  Sekuri et al. [@pone.0002533-Sekuri1]                              CHD                                                                                                                              At least one stenosis ≥ 50% in a major coronary artery or one of their branches                                                                                                                                                      Healthy subjects without history of CVD
  Methot et al. [@pone.0002533-Methot1]                              CHD                                                                                                                          Acute coronary syndrome: AMI or unstable angina defined according to standard criteria                                                                                                                         Postmenopausal women without signs or symptoms of acute or previous acute coronary syndrome
  Renner et al. [@pone.0002533-Renner1]                            CHD, MI                                                                                        CHD: At least one stenosis ≥ 50% in one of 15 coronary segments MI: positive history of MI or patients presented with ST elevation or non-ST elevation                                                                                                       Subjects without CHD (with stenoses \<20%) from a cohort study
  Zafarmand et al. (present study)                                 CHD, MI                                                                                                                                  CHD: ICD, 9th edition, codes 410-414 MI: ICD, 9th edition, code 410                                                                                                                                       Members of a 10% random sample from the whole cohort at the baseline without CVD
  Kamitani et al. [@pone.0002533-Kamitani1]                          MI                                                                                                                      Having MI by coronary angiography, ECG criteria, and measurements of heart-specific serum enzymes                                                                                                                               Randomly selected subjects attending the same hospital with no CVD
  Ishigami et al. [@pone.0002533-Ishigami1]                          CHD                                                                                                         At least one coronary artery with \>25% luminal obstruction on average according to multiple coronary angiographic views                                                                                                                         Hospital-admitted patients for other diseases with no CHD
  Yamakawa-Kobayashi et al. [@pone.0002533-YamakawaKobayashi1]       CHD                                                                                                                                              At least one 75% stenosis in coronary arteries                                                                                                                                                                                  Healthy controls
  Ko et al. [@pone.0002533-Ko1]                                      CHD                                                                                                                                           \>50% stenosis of at least one major coronary vessel                                                                                                                                                      Healthy subjects and patients without angiographic evidence of CHD
  Ichihara et al. [@pone.0002533-Ichihara1]                          CHD      MI was based on typical ECG changes and increased serum enzymes and by the presence of wall motion abnormality on left ventriculography, Angina pectoris by typical ECG changes and stenosis of \>70% in any major coronary artery or of \>50% in the left main trunk, without wall motion abnormality on left ventriculography      Random healthy controls with no history or sign of CHD from attendants of the hospitals
  Cong et al. [@pone.0002533-Cong1]                                  CHD                                                                                                                                           ≥ 50% stenosis in at least one major coronary artery                                                                                                                                                     Subjects with no history of CHD or abnormal resting electrocardiogram
  Sheu et al. [@pone.0002533-Sheu1]                                  CHD                                                                                                           A postnitroglycerin stenosis of major vessels ≥ 50% or a \>70% reduction of luminal diameter of a first-order branche                                                                                                                             Healthy subjects in their annual physical checkups
  Tsai et al. [@pone.0002533-Tsai1]                                  CHD                                                                                                                                              \>50% stenosis of at least one coronary vessel                                                                                                                                                                      CHD-free group documented by angiography
  Frossard et al. [@pone.0002533-Frossard1]                        CHD, MI                                                                            CHD: Exertional angina, unstable angina or MI MI: ECG changes; presence of regional wall motion abnormalities on trans-thoracic echocardiography; and serial enzyme elevations                                                                                                                  Healthy controls
  Hooper et al. [@pone.0002533-Hooper1]                              MI                                                                                                                      Prior MI confirmed by ECG and/or cardiac enzymes or cardiac thallium scanning or catheterization                                                                                                                                Outpatients with no history of heart attack, stroke, or thrombosis
  Nair et al. [@pone.0002533-Nair1]                                  CHD                                                                                                                                              At least one coronary artery with 50% stenosis                                                                                                                                                            Healthy controls with BP\<140/90 mm Hg and no history of CVD
  Araujo et al. [@pone.0002533-Araujo1]                              MI                                                                                                              Using the WHO criteria confirmed by stenosis \>50% in an angiography and ventricular damage in a ventriculography                                                                                                                Hospital-admitted patients for other diseases with a normal coronary angiography
  Ranjith et al. [@pone.0002533-Ranjith1]                            MI                                                                                                                                                           Using the WHO criteria                                                                                                                                                                 Healthy normotensive subjects with no CVD or other associated risk factors

PTCA, percutaneous coronary angioplasty; CABG, coronary artery bypass graft; ICD, international classification of diseases; ECG, electrocardiography; AMI, acute myocardial infarction; CHD, coronary heart disease; CVD, cardiovascular diseases; CVA, cerebrovascular accident; BMI, body mass index; WHO, world health organization; NR, not reported.

Exact significance probability.

All studies used polymerase chain reaction methods for genotyping, and most used a restriction fragment length method for polymorphism analysis. Blinding of investigators involved in genotyping with respect to the case/control status of the participants was reported in six studies [@pone.0002533-RodriguezPerez1], [@pone.0002533-Bis1], [@pone.0002533-Reinhardt1], [@pone.0002533-Renner1], [@pone.0002533-Wierzbicki1]. A random double-check to detect potential genotyping errors was mentioned in five studies [@pone.0002533-FernandezArcas2], [@pone.0002533-Reinhardt1], [@pone.0002533-Tobin1], [@pone.0002533-Wierzbicki1]. In most of the studies, the genotype frequencies were consistent with HWE. However, statistically significant deviations from HWE were found in five studies ([Table 3](#pone-0002533-t003){ref-type="table"}) [@pone.0002533-Buraczynska1], [@pone.0002533-Cong1], [@pone.0002533-Fatini1], [@pone.0002533-Ishigami1], [@pone.0002533-Reinhardt1]. CHD cases were defined in 16 studies as a \>50% stenosis of at least one coronary vessel [@pone.0002533-Olivieri1], [@pone.0002533-RodriguezPerez1], [@pone.0002533-Sekuri1], [@pone.0002533-Nair1], [@pone.0002533-Cong1], [@pone.0002533-Gardemann1], [@pone.0002533-Hooper1], [@pone.0002533-Ishigami1], [@pone.0002533-Ko1], [@pone.0002533-Ortlepp1], [@pone.0002533-Reinhardt1], [@pone.0002533-Renner1], [@pone.0002533-Tsai1]--[@pone.0002533-Winkelmann1], while, in four studies, a \>70% stenosis was considered [@pone.0002533-Fatini1], [@pone.0002533-Ichihara1], [@pone.0002533-Sheu1], [@pone.0002533-YamakawaKobayashi1]. In 14 studies [@pone.0002533-Tiret1], [@pone.0002533-Sethi3]--[@pone.0002533-Bis1], [@pone.0002533-Ermis1], [@pone.0002533-FernandezArcas2]--[@pone.0002533-Frossard1], [@pone.0002533-Kamitani1], [@pone.0002533-Methot1], [@pone.0002533-Ranjith1], [@pone.0002533-Tobin1], the WHO criteria were used, and, in four studies, CHD was diagnosed based on a clinical diagnosis [@pone.0002533-Ludwig1], [@pone.0002533-Buraczynska1], [@pone.0002533-Katsuya1]. Controls arose from the source population of the cases in 21 studies [@pone.0002533-Ludwig1], [@pone.0002533-RodriguezPerez1], [@pone.0002533-Tiret1], [@pone.0002533-Sethi3], [@pone.0002533-Batalla1]--[@pone.0002533-Buraczynska1], [@pone.0002533-Ermis1]--[@pone.0002533-Fomicheva1], [@pone.0002533-Katsuya1], [@pone.0002533-Methot1], [@pone.0002533-Ranjith1]--[@pone.0002533-Tobin1], [@pone.0002533-Wenzel1], while hospital-based/not population-based controls were used in 17 studies [@pone.0002533-Olivieri1], [@pone.0002533-Sekuri1], [@pone.0002533-Nair1], [@pone.0002533-Araujo1], [@pone.0002533-Cong1], [@pone.0002533-Frossard1]--[@pone.0002533-Kamitani1], [@pone.0002533-Ko1], [@pone.0002533-Ortlepp1], [@pone.0002533-Tsai1], [@pone.0002533-Wierzbicki1]--[@pone.0002533-YamakawaKobayashi1].

Quantitative data synthesis {#s3d}
---------------------------

The overall OR under a random-effects model using an additive model for CHD risk was 1.08 (95% CI, 1.01 to 1.15; *P* = 0.025; [Figure 2](#pone-0002533-g002){ref-type="fig"}). However, there was evidence of substantial between-study heterogeneity (***I^2^*** = 55.5%, *P*\<0.001). [Table 4](#pone-0002533-t004){ref-type="table"} shows the association of the *AGT* T235M polymorphism with CHD risk under different genetic contrasts. When a recessive model was evaluated, a significant association was found between individuals homozygous for the T allele (T235T genotype) and CHD risk, when compared to carriers of the M allele (OR = 1.11; 95% CI, 1.02 to 1.22; *P* = 0.016). Under the dominant model, the association was not significant. Under pairwise comparisons, there was a significant modest association between the T235T genotype and CHD risk, as compared with the M235M genotype (OR = 1.15; 95% CI, 1.00 to 1.32; *P* = 0.045). There was evidence for moderate to large between-study heterogeneity under all models ([Table 4](#pone-0002533-t004){ref-type="table"}). Sub-group analysis, by study characteristics under the additive model, showed that matching, blinding of genotyping staff, and regenotyping of a random sub-sample explained little of the heterogeneity. However, stratification showed an attenuated effect estimates in the large studies, in studies that CHD was defined based on angiography or WHO criteria, and in particular in studies that were in HWE ([Table 5](#pone-0002533-t005){ref-type="table"}). Further evaluation of potential sources of the heterogeneity was performed using a meta-regression analysis.

![Results of published studies of association between the M235T polymorphism in *AGT* gene and coronary heart disease in different ethnic groups.\
ORs for the outcome compared the T235 allele vs. the M235 allele (Additive model). The size of the box is proportional to the weight of the study. Given *P*-values for odds ratios are based on DerSimonian-Laird method using a random effects model and for heterogeneity in different ethnic groups are based on Q-test.](pone.0002533.g002){#pone-0002533-g002}
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###### ORs and 95% CI for coronary heart disease and the M235T polymorphism in *AGT* gene under different genetic models.

![](pone.0002533.t004){#pone-0002533-t004-4}

  Genetic model                                Random effects OR (95% CI)   *P*-value   *I^2^* (%) (95% CI)   ***Q*** statistic for heterogeneity (df = 37)   *P*-value for heterogeneity   Egger\'s test *P*-value   Begg\'s test *P*-value
  ------------------------------------------- ---------------------------- ----------- --------------------- ----------------------------------------------- ----------------------------- ------------------------- ------------------------
  Additive [a](#nt112){ref-type="table-fn"}        1.08 (1.01--1.15)          0.025        55.5 (36--69)                          83.21                                 \<0.001                      0.066                    0.074
  Recessive (TT vs. M-carriers)                    1.11 (1.02--1.22)          0.016        37.5 (7--58)                           59.23                                  0.012                       0.011                    0.070
  Dominant (T-carriers vs. MM)                     1.07 (0.96--1.19)          0.253        56.0 (37--69)                          84.02                                 \<0.001                      0.549                    0.706
  MT vs. MM                                        1.02 (0.91--1.14)          0.724        51.3 (29--66)                          75.99                                 \<0.001                      0.895                    0.960
  TT vs. MM                                        1.15 (1.00--1.32)          0.045        53.3(33--68)                           79.30                                 \<0.001                      0.286                    0.615

The additive genetic model assumes that there is a linear gradient in risk between the MM, MT and TT genotypes (MM genotype baseline). This is equivalent to a comparison of the T allele versus the M allele (baseline).

10.1371/journal.pone.0002533.t005

###### Studies of the M235T polymorphism in *AGT* gene and risk of coronary heart disease under additive model grouped by study characteristics.

![](pone.0002533.t005){#pone-0002533-t005-5}

  Study characteristics                 Number of studies   Per-allele OR (95%CI)   *P*-value   ***I^2^*** (%) (95%CI)   ***Q*** statistic for heterogeneity   *P*-value for heterogeneity
  ------------------------------------ ------------------- ----------------------- ----------- ------------------------ ------------------------------------- -----------------------------
  Overall                                      38             1.08 (1.01--1.15)       0.025         55.5 (36--69)                       83.21                            \<0.001
  Study size                                                                                                                                                  
  Small                                        26             1.12 (1.02--1.24)       0.021         50.2 (35--73)                       50.24                             0.002
  Large                                        12             1.03 (0.95--1.12)       0.502         62.0 (29--80)                       28.92                             0.002
  Ethnicity                                                                                                                                                   
  Caucasians                                   25             1.08 (1.01--1.17)       0.028         58.2 (35--73)                       57.43                            \<0.001
  Eastern Asians                                8             1.12 (0.89--1.40)       0.325         69.5 (36--85)                       22.96                             0.002
  Others                                        5             0.99 (0.84--1.18)       0.944          0.00 (0--79)                       2.31                              0.679
  Matching                                                                                                                                                    
  Matched                                      11             1.07 (0.96--1.18)       0.211          26.2 (0--63)                       13.56                             0.194
  Unmatched                                    27             1.08 (0.99--1.17)       0.072         62.7 (44--75)                       69.65                            \<0.001
  Violating HWE                                                                                                                                               
  Violated                                      5            1.38 (1.05,--1.83)       0.022         70.7 (26--88)                       13.65                             0.009
  Confirmed                                    33             1.04 (0.98--1.11)       0.188          43.5 (5--63)                       56.66                             0.005
  Blinding of genotyping staff                                                                                                                                
  Blinded                                       6             1.07 (0.92--1.24)       0.391          62.6 (9--85)                       13.36                             0.020
  Not reported                                 32             1.08 (1.00--1.16)       0.040         55.5 (34--70)                       69.88                            \<0.001
  Regenotyping of a random subsample                                                                                                                          
  Performed                                     5             0.94 (0.79--1.14)       0.544          58.9 (0--85)                       9.74                              0.045
  Not reported                                 33             1.10 (1.03--1.18)       0.007         54.7 (33--69)                       70.64                            \<0.001
  Case definition                                                                                                                                             
  \>50%stenosis of ≥1 major vessels            16             1.09 (0.97--1.23)       0.135         62.4 (35--78)                       39.9                             \<0.001
  \>70%stenosis of ≥1 major vessels             4             1.10 (0.90--1.34)       0.358          40.7 (0--80)                        5.1                              0.167
  WHO criteria                                 14             1.00 (0.93--1.09)       0.942          36.9 (0--67)                       20.6                              0.081
  Clinical diagnosis                            4             1.31 (1.15--1.49)      \<0.001         0.00 (0--85)                        2.7                              0.439
  Source of controls                                                                                                                                          
  Population-based                             21             1.09 (1.01--1.19)       0.036         62.6 (40--77)                       53.5                             \<0.001
  Hospital-based                               17             1.05 (0.95--1.17)       0.354          44.6 (2--69)                       28.9                              0.025

Meta-regression {#s3e}
---------------

First, an empty regression was run with only the log of the effect estimate of pooled studies under the additive model to determine the baseline value for τ^2^, an estimate of between-study variation (baseline τ^2^ = 0.025). Next, single covariates were added in a series of univariate models. We performed the regression analysis for ten pre-defined potential sources of heterogeneity, including ethnicity, sex, mean age of cases, study size, case definition, source of controls, HWE-violation, blinding in genotyping, performing a sub-sample regenotyping, and matching (we hypothesized that studies that used matching might produce more conservative estimates of association). Univariate regression analyses showed that violation of HWE (β coefficient = 0.27 (0.06 to 0.48); *P~Het~* = 0.015, τ^2^ = 0.019), the mean age of cases (β = −0.01 (−0.02 to 0.0008); *P~Het~* = 0.066, τ^2^ = 0.024), and the method of case definition, clinically diagnosed CHD versus WHO criteria adjusted for other definitions (β = 0.26 (0.02 to 0.50); *P~Het~* = 0.038, τ^2^ = 0.020), were significant sources of heterogeneity among studies. The study size (*P~Het~* = 0.241, τ^2^ = 0.024), the ethnicity (*P~Het~* = 0.591, τ^2^ = 0.025), the male percentage in the study (*P~Het~* = 0.701, τ^2^ = 0.029), blinded genotyping (*P~Het~* = 0.890, τ^2^ = 0.026), sub-sample regenotyping (*P~Het~* = 0.131, τ^2^ = 0.023), the source of controls (*P~Het~* = 0.640, τ^2^ = 0.025), and matching (*P~Het~* = 0.942, τ^2^ = 0.026) were not significant sources of heterogeneity among studies. Violation of HWE in multivariable regression analysis remained a statistically significant source of heterogeneity after adjustment for the effect of study size (*P~Het~* = 0.031, τ^2^ = 0.020). Adding the mean age of cases and method of case definition to the model with violation of HWE decreased the τ^2^ value to 0.017 (*P~Het~* = 0.073 for violation of HWE, *P~Het~* = 0.057 for the mean age of cases, and *P~Het~* = 0.162 for clinically diagnosed CHD). It also showed that the effect of method of case definition on the variation among the studies was through the effect of the mean age on the heterogeneity and not as an independent factor. A model that included only violation of HWE and the mean age of cases reduced the τ^2^ value to 0.018 (*P~Het~* = 0.019, and 0.052, respectively).

Sensitivity Analysis {#s3f}
--------------------

First, the influence of deviation from the HWE on effect estimates was examined by using HWE-deviated adjusted ORs. [Table 6](#pone-0002533-t006){ref-type="table"} presents the genotype-based contrasts with corrected ORs, as well as the allele-based contrast. After adjustment, a smaller overall effect was seen under the additive, dominant, and pairwise comparisons. Moreover, after adjustment, the previously significant association under the additive model, as well as the TT vs. MM comparison, was no longer statistically significant. The association under the recessive model still remained significant.

10.1371/journal.pone.0002533.t006

###### ORs and 95% CI after adjustment for HWE-deviation under different genetic models.

![](pone.0002533.t006){#pone-0002533-t006-6}

  Genotype contrasts    Population    Number of studies   Random effects model   *I^2^* (%) (95%CI)   *Q* statistic for heterogeneity   *P*-value for heterogeneity          
  -------------------- ------------- ------------------- ---------------------- -------------------- --------------------------------- ----------------------------- ------- ---------
  Additive                  All              38                   1.11               0.81--1.53                    0.522                         0 (0--37)            2.04     1.000
                        Caucasians           25                   1.11               0.75--1.64                    0.616                         0 (0--44)            1.04     1.000
                        East Asians           8                   1.19               0.60--2.36                    0.626                         0 (0--68)            0.82     0.997
  Recessive                 All              38                   1.14               1.04--1.26                    0.007                        56 (37--70)           84.66   \<0.001
                        Caucasians           25                   1.15               1.03--1.29                    0.014                        56 (32--72)           55.02   \<0.001
                        East Asians           8                   1.18               0.90--1.55                    0.242                        73 (45--87)           26.15   \<0.001
  Dominant                  All              38                   1.05               0.96--1.15                    0.330                        49 (26--65)           72.52   \<0.001
                        Caucasians           25                   1.08               0.98--1.20                    0.121                        58 (35--73)           57.82   \<0.001
                        East Asians           8                   0.92               0.64--1.33                    0.656                        33 (0--70)            10.41    0.166
  MT vs MM                  All              38                   1.00               0.92--1.09                    0.996                        15 (0--43)            43.41    0.217
                        Caucasians           25                   1.03               0.94--1.14                    0.497                        25 (0--54)            31.99    0.127
                        East Asians           8                   0.82               0.60--1.11                    0.204                         0 (0--68)            6.53     0.480
  TT vs MM                  All              38                   1.13               0.99--1.28                    0.080                        52 (31--67)           77.88   \<0.001
                        Caucasians           25                   1.19               1.02--1.38                    0.023                        60 (38--74)           60.11   \<0.001
                        East Asians           8                   1.01               0.65--1.59                    0.952                        50 (0--77)            13.87    0.054

[Figure 3](#pone-0002533-g003){ref-type="fig"} shows a funnel plot in which the log of the OR of CHD risk under the additive genetic model was plotted against the standard error of the log of the OR in each study. The funnel plot for the overall results was substantially asymmetric for small negative studies. Moreover, tests for potential publication bias (The Egger\'s test and the Begg-Mazumdar test; *P*-values equal to 0.066 and 0.074, respectively) suggested the presence of a publication bias. By using the trim and fill method, we showed that, if the publication bias was the only source of the funnel plot asymmetry, it needed seven more studies to be symmetrical ([Figure 4](#pone-0002533-g004){ref-type="fig"}).

![Begg\'s funnel plot with pseudo 95% confidence limits under the additive genetic model.\
The size of the circle is proportional to the weight of the study.](pone.0002533.g003){#pone-0002533-g003}

![Filled Begg\'s funnel plot with pseudo 95% confidence limits under the additive genetic model.\
Red squares are missed studies due to publication bias.](pone.0002533.g004){#pone-0002533-g004}

Discussion {#s4}
==========

Prospect-EPIC study {#s4a}
-------------------

In this prospective study of healthy women aged 49 to 70 years, we investigated the relationship between the M235T polymorphism in the *AGT* gene and risk of AMI and CHD later in life. Under the additive genetic model, increased risks, albeit not statistically significant, were found for the incidence of AMI and CHD, which did not alter after adjustment. Likewise, we did not find a clear association between the variant and risk of CHD or AMI using different genetic models. This may be explained by: (i) the absence of a biological effect, (ii) the presence of real genetic heterogeneity according to ethnic background, or (iii) failure to detect a small effect because the epidemiologic risk for an individual genetic variant is likely to be small and a large sample size is needed for adequate statistical power. It has been commonly proposed that, as well as a need for much larger and more rigorous studies those that are currently used, there is a greater need for international collaborations, particularly for a complex disease like CHD [@pone.0002533-Seminara1].

### Strengths and limitations {#s4a1}

In our study, the data collection was prospective, before the diagnosis of AMI or CHD and equal for all participants. This ensures that the cases and the randomly selected controls are comparable [@pone.0002533-Prentice1]. For a multifactorial trait, like CHD, this provides a valid approach to evaluate the relationship between genetic factors and the risk of AMI and CHD, while taking into account co-existing and risk-modifying factors. In this study, prevalent cases of CHD were excluded from the analyses to prevent introducing bias due to potentially selective survival. The Prospect study was a population-based cohort, which makes it less susceptible to selection bias. Additional strengths were the comprehensiveness of our data and sample collection, as well as the morbidity and mortality follow-up for the entire cohort through linkage with nation-wide registries. The case-cohort design of the study combined the advantages of cohort studies (multiple outcomes and time-dependent covariates) with those of case-control analyses (fewer subjects); thus, it was more efficient than cohort studies. Classical case-control studies might be affected by selection bias since only non-fatal cases can be included, which was not the case in this study because of our endpoint definition. Moreover, we did not have misclassification of exposure (genotypes), which, when present, generally lead to a bias toward the null because we used standard laboratory protocols, performed a random double-check to detect potential genotyping errors, and had our *AGT* genotypes in Hardy-Weinberg equilibrium. The limitations of this study were the relatively short period of follow-up and the small number of cases. Moreover, because this cohort was exclusively composed of Dutch women, these results cannot be generalized to men or other ethnic groups, for whom the rates of the events or the allele frequency are known to differ.

Meta-Analysis {#s4b}
-------------

The current meta-analysis, which includes new data from a prospective study in a large population-based cohort of Dutch women, represents a comprehensive evaluation of the M235T variant of the *AGT* gene in CHD risk. Although a pooled per-allele OR was suggestive of a modest increase in the risk of CHD of 1.08 (95% CI, 1.01 to 1.15), the robustness of this summary estimate is uncertain. First, in the pre-specified sub-groups analyses in the meta-analysis, larger studies, those with validated genotyping quality controls, and studies that used standardized criteria for case definition did not provide strong evidence for a positive statistically significant association between the M235T variant of the *AGT* gene and CHD risk. Second, the meta-regression analysis revealed that the HWE violation was a significant source of the moderate to large heterogeneity in the meta-analysis. Taking violation of HWE into account in the meta-analysis decreased the overall effect ([Table 5](#pone-0002533-t005){ref-type="table"}). Third, the previous result was confirmed by using HWE-deviation adjusted ORs in the meta-analysis ([Table 6](#pone-0002533-t006){ref-type="table"}). Moreover, there was evidence for publication bias in the meta-analysis. Taken together, these findings point to a violation of HWE and publication biases as the potential explanations for the results observed in the meta-analysis.

Some aspects of the current meta-analysis need to be considered to appreciate the findings. First, it might not be very practical to adjust for violation of HWE in the studies that mentioned that the violation is not due to genotyping errors. However, in the current meta-analysis, the HWE-violated studies that were included in the pooled estimate did not provide any reason for the violation. Therefore, we performed sensitivity analyses by using HWE-adjusted ORs and corresponding variances. Thereafter, a smaller overall effect was seen under most of the genetic models. Second, the power of tests for HWE and the power to detect genotyping errors are low. Therefore, the inability to detect a deviation from the HWE does not mean that there is no deviation, nor does it rule out the presence of genotyping errors, especially for small sample sizes. Third, our meta-analysis was based on published studies and we did not have access to the original data. However, it could be possible that an association between the genotype and disease exists in certain contexts rather than in all people studied. For example, a case-control study showed that the TT genotype was associated with an increased risk of CHD and MI only in smokers [@pone.0002533-Buraczynska1]. Finally, in all meta-analyses of gene-disease association studies, the inclusion criteria of cases and controls can be a potentially confounding factor. In this meta-analysis, cases were well defined and the source of controls was not a significant source of variation. However, the advantages of this study were the large sample size of the meta-analysis of 38 studies with 13284 cases and 18722 controls, which was twice the number of studies and sample sizes that had been reported in the previous meta-analysis [@pone.0002533-Sethi2], the exploration of potential sources of heterogeneity in the meta-analysis, and the evaluation of the association under different modes of inheritance.

Approximately 10% of gene-disease association studies are affected by statistically significant deviation from HWE, which could result from genotyping error, chance, inbreeding, non-random mating, differential survival of marker carriers, genetic drift, population stratification, or a combination of these reasons [@pone.0002533-Trikalinos1], [@pone.0002533-Salanti1]. Of these, genotyping error could be avoided by using standard genotyping methods and performing quality assessment. It has been recommended that authors specify the quality measures for the genotyping analysis, such as the blinding of laboratory staff to the donor subjects and hypotheses being investigated, procedures for establishing duplicates, degree of reproducibility between quality control replicates, and the inspection for conformity to HWE [@pone.0002533-Little1]. In the current meta-analysis, in studies where the blinding of genotyping staff was not reported, a statistically significant increased risk of CHD was found, while those that used blinding methods did not find a significant association. Moreover, for studies without regenotyping of a random sub-sample, a significant increase in CHD risk was found, but not for studies that performed regenotyping. Although overlapping confidence intervals for before-mentioned risks indicate caution in any interpretations, no report on blinding and regenotyping can point towards an uncertainty in quality control of genotyping in these studies. However, violation of HWE, which tends to inflate the chance of a false positive association, may be the strongest indicator of genotyping error [@pone.0002533-Xu1].

Violation of HWE cannot solely explain the observed between-study variation in gene-disease association studies. The large between-study heterogeneity presented in most meta-analyses could be due to true heterogeneity (i.e., racial differences or differences in gene-environment interactions among various populations) or bias [@pone.0002533-Ntzani1]. Bias, which could invalidate the results of the studies, should, therefore, be explored in detail. Biological plausibility, publication bias, selection bias, biased definition of cases, biased selection of controls, and population stratification should be assessed [@pone.0002533-Ntzani1]. In this meta-analysis, we found strong evidence for publication bias. This is said to occur when the chance of the publication of a smaller study increases when it shows a stronger effect. Further exploration for sources of biases among studies showed that the selection of controls was not biased. However, using different case definitions resulted in a significant difference in the risk of CHD between those studies using WHO criteria and those using clinically diagnoses of CHD. Studies using definition of cases based on coronary angiography or based on WHO criteria had the same results. Considering a multivariate model in the meta-regression results, case definition was not a significant source of bias in the meta-analysis, while the different mean age of cases and violation of HWE were significant sources of heterogeneity. Since increasing age is a risk factor for CHD and the mean age of cases in the included studies ranged from 42 to 67 years, it is more likely that the studies with older individuals would show a stronger effect and produce heterogeneity. As case-parental controls, or other family-based designs, and genomic controls, using unlinked genetic markers which have no effect on the risk of CHD, were not available to evaluate the potential problem of population stratification among the studies, we presented effect estimates by different ethnic groups. However, there is controversy about the potential importance of population stratification for genetic-association studies using unrelated subjects [@pone.0002533-Wacholder1].

In conclusion, the present meta-analysis, including our own data, indicated that, although a weak association between the M235T variant in the *AGT* gene and CHD was found, the relevance of this weakly positive overall association remains uncertain because it may be due to various residual biases. Moderate to large heterogeneity was identified between studies, and violation of HWE and the mean age of cases were statistically significant sources of the observed variation.
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